Trial Profile
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab for Relapse of Primary Malignancy After Allogeneic Hematopoietic Stem Cell Transplant: A Feasibility Study
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Nov 2022 Status changed from recruiting to discontinued.
- 31 Mar 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Aug 2022.
- 26 May 2021 Planned End Date changed from 1 Apr 2022 to 1 Nov 2022.